MISSISSAUGA, ON, May 11, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2017 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 5, 2017 were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
Director Nominees | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Daniel Chicoine | 2,997,859 | 82,678 | 97.32 | 2.68 |
David A. Copeland | 2,999,892 | 80,645 | 97.38 | 2.62 |
Anthony E. Dobranowski | 3,002,978 | 77,559 | 97.48 | 2.52 |
Robert Harris | 3,011,591 | 68,946 | 97.76 | 2.24 |
John C. London | 2,999,920 | 80,617 | 97.38 | 2.62 |
Dr. Jacques Messier | 2,999,298 | 81,239 | 97.36 | 2.64 |
About Nuvo Pharmaceuticals Inc.
Nuvo (TSX:NRI) is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes, Québec. For additional information, please visit www.nuvopharmaceuticals.com.
SOURCE Nuvo Pharmaceuticals Inc.
